{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kohanbash G"],"funding":["NCI NIH HHS","NINDS NIH HHS","NIGMS NIH HHS"],"pagination":["1425-1437"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5373859"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["127(4)"],"pubmed_abstract":["Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among the first genetic alterations observed during the development of lower-grade glioma (LGG). LGG-associated IDH mutations confer gain-of-function activity by converting α-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2HG). Clinical samples and gene expression data from The Cancer Genome Atlas (TCGA) demonstrate reduced expression of cytotoxic T lymphocyte-associated genes and IFN-γ-inducible chemokines, including CXCL10, in IDH-mutated (IDH-MUT) tumors compared with IDH-WT tumors. Given these findings, we have investigated the impact of IDH mutations on the immunological milieu in LGG. In immortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutant IDH1 or treatmen"],"journal":["The Journal of clinical investigation"],"pubmed_title":["Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas."],"pmcid":["PMC5373859"],"funding_grant_id":["P50 CA097257","R21 NS083171","R01 CA169316","T32 GM008568","T32 CA151022","R21 NS093654","R01 NS055140"],"pubmed_authors":["Kohanbash G","Okada H","Herold-Mende C","Warta R","Chheda ZS","Mazor T","Beppler C","Amankulor NA","Ahn BJ","Jahan N","Carrera DA","Costello JF","Shrivastav S","Downey KM","Watchmaker PB"],"additional_accession":[]},"is_claimable":false,"name":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.","description":"Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among the first genetic alterations observed during the development of lower-grade glioma (LGG). LGG-associated IDH mutations confer gain-of-function activity by converting α-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2HG). Clinical samples and gene expression data from The Cancer Genome Atlas (TCGA) demonstrate reduced expression of cytotoxic T lymphocyte-associated genes and IFN-γ-inducible chemokines, including CXCL10, in IDH-mutated (IDH-MUT) tumors compared with IDH-WT tumors. Given these findings, we have investigated the impact of IDH mutations on the immunological milieu in LGG. In immortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutant IDH1 or treatmen","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2026-05-30T07:35:12.159Z","creation":"2025-07-28T03:03:56.391Z"},"accession":"S-EPMC5373859","cross_references":{"pubmed":["28319047"],"doi":["10.1172/jci90644","10.1172/JCI90644"]}}